Alliance Foundation Trials, Llc.

This study tested whether adding a 2-year course of palbociclib to standard hormone therapy (given for at least 5 years) helps prevent breast cancer from returning in people with HR+/HER2- early breast cancer. About 5,800 participants with stage II or III cancer took part. The ma…

This study compares active monitoring (regular check-ups without immediate treatment) to surgery for people with low-risk ductal carcinoma in situ (DCIS), a non-invasive breast condition. About 997 participants are being followed for 2 years to see if monitoring leads to similar …

This study tests whether adding the drug palbociclib to standard hormone and anti-HER2 therapy can help people with a specific type of advanced breast cancer (HR+/HER2+) live longer without their cancer growing. About 518 adults with metastatic breast cancer that cannot be surgic…

This study tests a combination of four drugs (lenalidomide, ixazomib, dexamethasone, and daratumumab) in people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding two extra drugs to standard maintenance therapy helps keep th…

This study tests a combination of two targeted drugs, palbociclib and ibrutinib, in people with mantle cell lymphoma that has been treated before but returned. The goal is to see if the combination can control the cancer for longer. About 39 adults will take the drugs in 28-day c…

This study tests whether adding an extra immunotherapy drug (tiragolumab) to standard chemo, radiation, and atezolizumab can help people with stage III lung cancer live longer without the disease getting worse. About 178 adults with newly diagnosed, inoperable stage III NSCLC wil…

This study looks at how two different prostate cancer medications, darolutamide and enzalutamide, affect thinking skills like memory and attention. About 111 men with advanced prostate cancer will take one of the two drugs and complete computer-based brain tests over time. The go…